The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
In Vivo Targeted Delivery of Nanoparticles for Theranosis
Abstract
Therapy and diagnosis are two major categories in the clinical treatment of disease. Recently, the word "theranosis" has been created, combining the words to describe the implementation of these two distinct pursuits simultaneously. For successful theranosis, the efficient delivery of imaging agents and drugs is critical to provide sufficient imaging signal or drug concentration in the targeted disease site. To achieve this purpose, biomedical researchers have developed various nanoparticles composed of organic or inorganic materials. However, the targeted delivery of these nanoparticles in animal models and patients remains a difficult hurdle for many researchers, even if they show useful properties in cell culture condition. In this Account, we review our strategies for developing theranostic nanoparticles to accomplish in vivo targeted delivery of imaging agents and drugs. By applying these rational strategies, we achieved fine multimodal imaging and successful therapy. Our first strategy involves physicochemical optimization of nanoparticles for long circulation and an enhanced permeation and retention (EPR) effect. We accomplished this result by testing various materials in mouse models and optimizing the physical properties of the materials with imaging techniques. Through these experiments, we developed a glycol chitosan nanoparticle (CNP), which is suitable for angiogenic diseases, such as cancers, even without an additional targeting moiety. The in vivo mechanism of this particle was examined through rationally designed experiments. In addition, we evaluated and compared the biodistribution and target-site accumulation of bare and drug-loaded nanoparticles. We then focus on the targeting moieties that bind to cell surface receptors. Small peptides were selected as targeting moieties because of their stability, low cost, size, and activity per unit mass. Through phage display screening, the interleukin-4 receptor binding peptide was discovered, and we combined it with our nanoparticles. This product accumulated efficiently in atherosclerotic regions or tumors during both imaging and therapy. We also developed hyaluronic acid nanoparticles that can bind efficiently to the CD44 antigen receptors abundant in many tumor cells. Their delivery mechanism is based on both physicochemical optimization for the EPR effect and receptor-mediated endocytosis by their hyaluronic acid backbone. Finally, we introduce the stimuli-responsive system related to the chemical and biological changes in the target disease site. Considering the relatively low pH in tumors and ischemic sites, we applied pH-sensitive micelle to optical imaging, magnetic resonance imaging, anticancer drug delivery, and photodynamic therapy. In addition, we successfully evaluated the in vivo imaging of enzyme activity at the target site with an enzyme-specific peptide sequence and CNPs. On the basis of these strategies, we were able to develop self-assembled nanoparticles for in vivo targeted delivery, and successful results were obtained with them in animal models for both imaging and therapy. We anticipate that these rational strategies, as well as our nanoparticles, will be applied in both the diagnosis and therapy of many human diseases. These theranostic nanoparticles are expected to greatly contribute to optimized therapy for individual patients as personalized medicine, in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
A review of stimuli-responsive nanocarriers for drug and gene delivery
Ganta, S., Devalapally, H., Shahiwala, A., & Amiji, M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.017 · Cited by 2,155
Hyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Nanoparticle-based theranostic agents
Xie, J., Lee, S., & Chen, X. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.009 · Cited by 1,422
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Molecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Cited by
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Abasalizadeh, F., Moghaddam, S. V., Alizadeh, E., akbari, E., Kashani, E., Fazljou, S. M. B., Torbati, M., & Akbarzadeh, A. (2020) · Journal of Biological Engineering · doi:10.1186/s13036-020-0227-7 · Cited by 608
Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy
Zhong, Y., Meng, F., Deng, C., & Zhong, Z. (2014) · Biomacromolecules · doi:10.1021/bm5003009 · Cited by 541
Metabolism of Nanomaterials in Vivo: Blood Circulation and Organ Clearance
Wang, B., He, X., Zhang, Z., Zhao, Y., & Feng, W. (2013) · Accounts of Chemical Research · doi:10.1021/ar2003336 · Cited by 531
Nanotheranostics for personalized medicine
Mura, S., & Couvreur, P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.006 · Cited by 527
Diverse gatekeepers for mesoporous silica nanoparticle based drug delivery systems
Wen, J., Yang, K., Liu, F., Li, H., Xu, Y., & Sun, S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00219j · Cited by 477
Nanocarriers for drug delivery applications
Chamundeeswari, M., Jeslin, J., & Verma, M. L. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-018-00841-1 · Cited by 444
Choi, K. Y., Liu, G., Lee, S., & Chen, X. (2012) · Nanoscale · doi:10.1039/c1nr11277e · Cited by 437
Self-citationAi, X., Ho, C. J. H., Aw, J., Attia, A. B. E., Mu, J., Wang, Y., Wang, X., Wang, Y., Liu, X., Chen, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10432 · Cited by 433
Polymeric multilayer capsules for drug delivery
De Koker, S., Hoogenboom, R., & De Geest, B. G. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15296g · Cited by 383
Wang, J., Zhu, G., You, M., Song, E., Shukoor, M. I., Zhang, K., Altman, M. B., Chen, Y., Zhu, Z., Huang, C. Z., et al. (2012) · ACS Nano · doi:10.1021/nn300694v · Cited by 357
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Liu, Y., Ai, K., & Lu, L. (2012) · Accounts of Chemical Research · doi:10.1021/ar300150c · Cited by 345
Synthesis and Biomedical Applications of Multifunctional Nanoparticles
Kim, D., Shin, K., Kwon, S. G., & Hyeon, T. (2018) · Advanced Materials · doi:10.1002/adma.201802309 · Cited by 317
Smart Albumin‐Biomineralized Nanocomposites for Multimodal Imaging and Photothermal Tumor Ablation
Wang, Y., Yang, T., Ke, H., Zhu, A., Wang, Y., Wang, J., Shen, J., Liu, G., Chen, C., Zhao, Y., et al. (2015) · Advanced Materials · doi:10.1002/adma.201500229 · Cited by 313
Organelle-Targeted Photosensitizers for Precision Photodynamic Therapy
Wang, R., Li, X., & Yoon, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02019 · Cited by 293
Magnetite Nanostructured Porous Hollow Helical Microswimmers for Targeted Delivery
Yan, X., Zhou, Q., Yu, J., Xu, T., Deng, Y., Tang, T., Feng, Q., Bian, L., Zhang, Y., Ferreira, A., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201502248 · Cited by 282
Shiraishi, K., Hamano, M., Ma, H., Kawano, K., Maitani, Y., Aoshi, T., Ishii, K. J., & Yokoyama, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.016 · Cited by 141
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Mojica Pisciotti, M. L., Lima, E., Vasquez Mansilla, M., Tognoli, V. E., Troiani, H. E., Pasa, A. A., Creczynski‐Pasa, T. B., Silva, A. H., Gurman, P., Colombo, L., et al. (2014) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33068 · Cited by 87
Fu, L., Sun, C., & Yan, L. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am508291k · Cited by 78
Tawfik, S. M., Sharipov, M., Huy, B. T., Gerelkhuu, Z., Biechele-Speziale, D., & Lee, Y.-I. (2018) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2017.08.051 · Cited by 56
Metadata
- Authors
- Koo, H., Huh, M. S., Sun, I.-C., Yuk, S. H., Choi, K., Kim, K., & Kwon, I. C.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-08-18
- Volume
- 44
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W2035950553
- Cited by
- 447
- References
- 56
- FWCI
- 15.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.